Purple biotech appoints senior business development executive fabien sebille as chief business officer

Rehovot, israel, dec. 09, 2021 (globe newswire) -- purple biotech ltd. ("purple biotech", or the "company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of fabien sebille, ph.d., a senior business development executive with more than 15 years of professional experience in the biotechnology industry, as its chief business officer. dr. sebille, who has led a series of licensing deals in oncology over the last four years, will be primarily responsible for business development, including strategic partnering opportunities.
PPBT Ratings Summary
PPBT Quant Ranking